Publications by authors named "Rebecca A Herbertson"
Article Synopsis
- Platelet activation is linked to the spread of cancer, and ongoing trials are testing if aspirin can help prevent this process by reducing platelet activation.
- A study involving 716 cancer patients measured a specific biomarker (U-TXM) related to platelet activation after treatment and its relation to patient factors and aspirin use.
- Results showed that while lower doses of aspirin significantly reduced U-TXM levels across different cancer types, higher doses didn’t provide any additional benefit; elevated U-TXM levels suggest ongoing malignancy activity, especially in patients with colorectal and gastro-oesophageal cancers.
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Cochrane Database Syst Rev
June 2017
Background: Epidermal growth factor receptor (EGFR) inhibitors prevent cell growth and have shown benefit in the treatment of metastatic colorectal cancer, whether used as single agents or in combination with chemotherapy. Clear benefit has been shown in trials of EGFR monoclonal antibodies (EGFR MAb) but not EGFR tyrosine kinase inhibitors (EGFR TKI). However, there is ongoing debate as to which patient populations gain maximum benefit from EGFR inhibition and where they should be used in the metastatic colorectal cancer treatment paradigm to maximise efficacy and minimise toxicity.
View Article and Find Full Text PDFUnlabelled: huA33 is a humanized antibody that targets the A33 antigen, which is highly expressed in intestinal epithelium and more than 95% of human colon cancers but not other normal tissues. Previous studies have shown huA33 can target and be retained in a metastatic tumor for 6 wk but eliminated from normal colonocytes within days. This phase I study used radiolabeled huA33 in combination with capecitabine to target chemoradiation to metastatic colorectal cancer.
View Article and Find Full Text PDFPurpose: This phase I study explored the biodistribution and pharmacokinetics of the immunoconjugate CMD-193 [a humanized anti-Lewis Y (Le(y)) antibody conjugated with calicheamicin in patients with advanced cancers expressing the Le(y) antigen.
Experimental Design: The primary objectives were to determine biodistribution and pharmacokinetics of CMD-193. Secondary objectives included response rates and change in tumor metabolism.